Targeted therapy in cervical cancer
- PMID: 30997156
- PMCID: PMC6438352
- DOI: 10.1136/esmoopen-2018-000462
Targeted therapy in cervical cancer
Abstract
Cervical cancer continues to be a common cancer in women worldwide, especially in less developed regions where advanced stage presentations are common. Addition of bevacizumab to cytotoxic chemotherapy has been the only notable recent advance in the treatment of recurrent and metastatic cervical cancer. Outcomes in patients with locally advanced disease have also plateaued after meaningful gains were achieved with concomitant chemoradiation treatment. Recently, progress has been made in understanding the molecular aberrations in cervical cancer and new therapeutic modalities are emerging, including immune checkpoint inhibitors, therapeutic vaccines, antibody-drug conjugates, and others. In this review we will discuss the data and potential utility of these approaches.
Keywords: Cervical cancer; targeted therapy.
Conflict of interest statement
Competing interests: SG has the following disclosures: Institutional financial interests for conducted research: Roche, Sanofi, Johnson & Johnson, Amgen, Celltrion, Oncosten, Novartis, Intas, Eisai, Biocon. Non-remunerated activities—Advisory board: Roche, Sanofi, Dr. Reddy’s Laboratories, Biocon, Pfizer, Oncosten, Core Diagnostics. Leadership roles: Vice-President of the Indian Society of Medical and Paediatric Oncology. General Secretary of a non-governmental organisation ‘Women’s Cancer Institute—Tata Memorial Hospital’.
References
-
- Bruni L, Barrionuevo-Rosas L, Albero G. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in India. Summary report 2017.
-
- Ries LAG, Harkins D, Krapcho M, 2006. SEER cancer statistics review, 1975–2003. Available: https://seer.cancer.gov/csr/1975_2003/ [Accessed 9 Oct 2018].
-
- Gupta S, Maheshwari A, Parab P, et al. . Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIb squamous cervical cancer: a randomized controlled trial. J Clin Oncol 2018;36:1548–55. 10.1200/JCO.2017.75.9985 - DOI - PubMed
LinkOut - more resources
Full Text Sources